Klotho
Research OnlyAn anti-aging transmembrane protein linked to longevity in animal models. Mouse studies demonstrate 15-20% lifespan extension. Primate cognition data published in Nature Aging. Klotho Neurosciences developing therapeutic applications for neurodegenerative disease.
Alpha-Klotho · KL protein · Anti-aging protein
8 human studies
- Preclinical
- 78%
- Clinical
- 18%
Based on 45 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 55: no human RCT of klotho administration exists; strongest human evidence is controlled observational genetic-association data (KL-VS variant cohorts) and a 109-study observational meta-analysis of circulating klotho (42060134), so 1A=22 (observational n>=100), 1B=8 (observational/some concerns), 1C=12 (epidemiologic N>1,000), 1D=4 (indirect surrogate: genetic variant / circulating level, not direct klotho dosing), 1E=9 (extensive replicated preclinical program: KO 9363890, overexpression/lifespan 16123266, primate cognition 37400721, PD/schizophrenia models 41916755/42117259). Mechanism 88: 2A=40 (FGF23 obligate co-receptor; KO + overexpression genetic models abolish/confer the effect), 2B=24 (FGF23/phosphate, Wnt inhibition, IGF1 repression, NMDAR-GluN2B, Nrf2 pathways mapped), 2C=14 (in-vivo dose-response incl. primate low- vs high-dose dissociation), 2D=10 (in-vivo mammalian: mice + primates). Plausibility 69: 3A=28 (mechanism->surrogate cognition/plasticity established, surrogate->human benefit inferred), 3B=23 (coheres with aging/neurodegeneration biology), 3C=10 (limited same-class analogy), 3D=8 (multi-system claims: brain, kidney, CV, longevity). Global Coverage 73: 4A=28 (reproduced across independent groups/countries: Japan, US, China, Korea, Europe), 4B=22 (globally distributed), 4C=23 (>100 studies, growing; 42274849/42057473 reviews), 4D=0 (no regulatory review/IND anywhere). Community Experience 24: 5A=6 (negligible niche use - recombinant protein, not a consumer compound), 5B=4 (no real-world track record), 5C=5 (few reports), 5D=9 (no adverse signal but minimal exposure). Effectiveness not established: no quantified human efficacy estimate for klotho administration (primate cognition is animal; KL-VS is genetic association, not an intervention effect) and no meaningful community effect signal.
How It Works (Simplified)
Klotho is a naturally occurring transmembrane protein discovered in 1997 (PMID: 9363890) that functions as an aging suppressor. Mice deficient in klotho exhibit accelerated aging (PMID: 9363890), while overexpression of klotho extends lifespan (PMID: 16123266). The protein circulates in a soluble form (shed from cell membranes) and acts as a hormone influencing multiple organ systems including brain, kidney, and cardiovascular tissue.
Scientific Pathways
FGF23 Co-Receptor: Klotho serves as an obligate co-receptor for fibroblast growth factor 23 (FGF23), regulating phosphate metabolism and vitamin D synthesis in the kidney. This axis is critical for mineral homeostasis and its dysregulation contributes to age-related disease.
Wnt Signaling Inhibition: Klotho suppresses Wnt signaling, which when overactive drives cellular senescence and tissue fibrosis — key features of aging.
Neuroprotection: Soluble klotho enhances synaptic plasticity and cognitive function. Primate studies published in Nature Aging demonstrated cognitive enhancement following klotho administration, representing a major translational advance.
Antioxidant Defense: Klotho upregulates manganese superoxide dismutase (MnSOD) expression, reducing oxidative stress at the cellular level.
Clinical Evidence
Epidemiological Data: Human genetic studies show that klotho gene variants (KL-VS) are associated with longevity, higher cognitive function, and reduced cardiovascular disease risk. Carriers of the KL-VS heterozygous variant show enhanced cognition across age groups.
Primate Cognition Study: A landmark study in aged rhesus macaques demonstrated that a single administration of low-dose (but not high-dose) klotho protein enhanced memory, suggesting systemic low-dose klotho may prove therapeutic in aging humans (PMID: 37400721, Castner et al., Nature Aging 2023).
Mouse Longevity Data: Transgenic mice overexpressing klotho live longer than wild-type controls, with klotho functioning as a circulating anti-aging hormone that represses insulin/IGF1 signaling (PMID: 16123266, Kurosu et al. 2005).
Safety Profile
As a naturally occurring human protein, klotho has a favorable theoretical safety profile. However, therapeutic development is in early stages with no human clinical trials completed. Potential concerns include the complexity of recombinant protein manufacturing, delivery challenges (blood-brain barrier penetration for neurological applications), and unknown effects of supraphysiological klotho levels in humans.
Important Limitations
- No human clinical trials completed for therapeutic klotho administration
- Recombinant protein delivery challenges (stability, half-life, BBB penetration)
- Epidemiological associations do not prove causation
- Mouse lifespan data may not directly translate to humans
- Commercial therapeutic development is in very early stages
- Klotho levels decline naturally with age; restoration vs augmentation is an open question
Epithalon
CompatibleDifferent anti-aging mechanisms. Klotho modulates FGF23/mineral metabolism while epithalon targets telomerase. No known interactions.
Humanin
CompatibleBoth are longevity-associated proteins with non-overlapping mechanisms. Klotho targets FGF23/Wnt signaling while humanin is mitochondrial-derived.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Klotho
Related Peptides
Endoluten
Pineal cytamin · Pineal gland peptides · A-8 pineal peptides
A cytamin-class peptide supplement derived from pineal gland tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for pineal function and melatonin support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
FOXO4-DRI
FOXO4-D-Retro-Inverso · FOXO4-DRI Peptide · Proxofim
A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, selectively eliminating senescent cells (senolytic). Preclinical studies in aged mice demonstrated restored fitness, fur density, and renal function. No human clinical trials conducted. More selective than BCL-2 inhibitors but remains unproven in humans.
Glutathione
GSH · L-Glutathione · Reduced Glutathione +1
The master antioxidant and most abundant intracellular thiol in mammalian cells. This naturally occurring tripeptide (glutamate-cysteine-glycine) is essential for detoxification, immune function, and cellular protection. Extensively studied with strong mechanistic understanding and growing clinical evidence.
SHLP-2
Small Humanin-Like Peptide 2 · SHLP2 · Mitochondrial-Derived Peptide 2
A 26-amino acid mitochondria-derived peptide (MDP) discovered in 2016 from the same mitochondrial DNA region as humanin. Shows cytoprotective, metabolic, and potential longevity effects in preclinical studies. Part of an emerging class of mitochondrial signaling molecules, but human therapeutic data is lacking.
SHLP-6
Small Humanin-Like Peptide 6 · SHLP6 · Mitochondrial-Derived Peptide 6
A 22-amino acid mitochondria-derived peptide with the unique property of being pro-apoptotic—the opposite of its sister peptides humanin and SHLP-2. Discovered in 2016, SHLP-6 may have applications in cancer and senescent cell clearance. Research is very early-stage with minimal published data.
SS-31
Elamipretide · Bendavia · MTP-131
A first-in-class mitochondria-targeting tetrapeptide that binds cardiolipin on the inner mitochondrial membrane. Developed by Stealth BioTherapeutics for mitochondrial diseases, heart failure, and age-related macular degeneration. Phase 3 trials in primary mitochondrial myopathy did not meet primary endpoints, but Barth syndrome data was positive. Strong preclinical rationale with mixed clinical translation.